Sphenopalatine ganglion block for refractory COVID-19 headache: a descriptive case series

Coronavirus SARS-CoV-2 is responsible for the COVID-19 pandemic, and headache is reported in 6.5% to 34% of all cases. There is little published evidence on the pharmacological treatment of COVID-19 headache. This case series presents six COVID-19 infected patients with refractory headache in which...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Felipe Chiodini, Carone Neto, Gilson, Carone, Rebeca Santiago Duarte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080502/
https://www.ncbi.nlm.nih.gov/pubmed/33932392
http://dx.doi.org/10.1016/j.bjane.2021.04.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080502/
https://www.ncbi.nlm.nih.gov/pubmed/33932392
http://dx.doi.org/10.1016/j.bjane.2021.04.024

Ejemplares similares